首页
订购/客服:400-666-5481

BMS-303141

    
99.90%

BMS-303141

源叶(MedMol)
S87464 一键复制产品信息
943962-47-8
C19H15Cl2NO4S
424.2977
BMS303141; BMS-303141; BMS 303141; 3,5-dichloro-2-hydroxy-N-(4-methoxy-[1,1'-biphenyl]-3-yl)benzenesulfonamide;3,5-二氯-2-羟基-N-(4-甲氧基[1,1'-联苯]-3-基)苯磺酰胺
货号 规格 价格 上海 北京 珠海 重庆 武汉 购买数量
S87464-5mg买3赠1
99.90%

¥400.00

5 - - - -
S87464-10mg买3赠1
99.90%

¥722.00

4 - - - -
S87464-25mg买3赠1
99.90%

¥1140.00

4 - - - -
S87464-100mg买3赠1
99.90%

¥3230.00

3 - - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品
产品描述: BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 Μm
靶点: IC50: 0.13 uM (ACL);ATPCitrateLyase
体外研究: In HepG2 cells, BMS-303141 shows inhibition of total lipid syntheses with an IC50 of 8 μM. BMS-303141 shows no cytotoxicity up to 50 lM under a cell based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity.
体内研究: Chronic oral dosing of BMS-303141 in high-fat fed mice lowers approximate 20-30% plasma cholesterol and triglycerides, as well as 30-50% fasting plasma glucose. Chronic treatment with BMS-303141 shows a gradual inhibition of weight gain along with a reduction in adiposity without apparent changes in food intake. BMS-303141 shows an oral bioavailability of 55% but a relatively short half-life of 2.1 h.
参考文献: 1. Li JJ, et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11.
溶解性: soluble  in  DMSO
保存条件: -20℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 2.357 ml 11.784 ml 23.568 ml
5 mM 0.471 ml 2.357 ml 4.714 ml
10 mM 0.236 ml 1.178 ml 2.357 ml
50 mM 0.047 ml 0.236 ml 0.471 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×